Appointment of joint brokers

RNS Number : 5300X

Oncimmune Holdings PLC

27 November 2017

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Appointment of Joint Brokers

Nottingham, UK - 27 November 2017: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology today announces it has appointed Bryan, Garnier & Co. and Berenberg as Joint Brokers in addition to Zeus Capital, with immediate effect.  Zeus Capital will continue to act as Nominated Advisor to the Company.

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Giles Balleny, Hugh Kingsmill Moore

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Berenberg (Joint Broker)

Toby Flaux, Charlotte Sutcliffe

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com

 

END

 

 

APPPGGRAGUPMPGQ